Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 05:12:38 22/07/2026 pm IST			5-day change	1st Jan Change
46.69 ^EUR	-1.95%		-2.12%	+26.18%

17/07	Bayer Ag and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials	CI
17/07	BAYER AG : JP Morgan keeps its Buy rating	ZD

UBS maintains 'Buy' rating on Bayer - Target 52 euros

Published on 06/05/2026 at 04:49 pm IST - Modified on 06/05/2026 at 06:21 pm IST

dpa-AFX - Translated by Marketscreener - See original

Add MarketScreener to your sources

BAYER AG

-1.95%

ZURICH (dpa-AFX) - Swiss investment bank UBS has reiterated its 'Buy' rating on Bayer with a price target of 52 euros. Overnight court filings indicate that the agrochemical and pharmaceutical group is pursuing a two-pronged strategy to remand the glyphosate class-action lawsuit in the U.S. back to the Missouri state district court, analyst Matthew Weston wrote in a research note published on Friday./rob/gl/ajx

Publication of the original study: 05.06.2026 / 05:50 / GMT First dissemination of the original study: 05.06.2026 / Time not specified in study / Time zone not specified in study

-----------------------

dpa-AFX Broker - Trader News from dpa-AFX

-----------------------

Add MarketScreener to your sources

Latest news about Bayer AG

17/07	Bayer Ag and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials	CI
17/07	BAYER AG : JP Morgan keeps its Buy rating	ZD
15/07	Bayer, RAGT Enter Licensing Deal to Launch Hybrid Wheat Seeds	MT
15/07	ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer	MT
14/07	Where would AI lead Pharma in the long run?
14/07	BAYER AG : Gets a Buy rating from Barclays	ZD
14/07	Fitch Affirms Bayer Rating, Negative Outlook Amid Near-term Uncertainties	MT
13/07	EU member states can cushion fertilizer prices	DP
13/07	BAYER AG : UBS keeps its Buy rating	ZD
13/07	Pesticide makers stack wins against US environmental, public health groups	RE
13/07	BAYER AG : Jefferies sticks Neutral	ZD
13/07	Jefferies keeps Bayer at 'Hold', target €46	DP
12/07	Moody's Upgrades Bayer Outlook With Rating Affirmation on "Positive" Court Decision	MT
10/07	Bayer in the red despite an improved balance sheet structure thanks to Apollo	DP
10/07	European Equities Mixed in Friday Trading; Apollo Enters Bid for EasyJet	MT

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.5%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (39.1%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.7%), Switzerland (1%), Europe-Middle East-Africa (22.9%), United States (33.1%), North America (3.6%), China (7.6%), Asia-Pacific (8.9%), Brazil (9.6%), and Latin America (7.6%).

Employees

87,757

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company